Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 2
Submit an article Journal homepage
128
Views
25
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

Francesca Palandri Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Emanuela Ottaviani Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Federica Salmi Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Lucia Catani Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Nicola Polverelli Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Mauro Fiacchini Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Giovanni Martinelli Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
,
Michele Baccarani Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
&
Nicola Vianelli Department of Hematology and Clinical Oncology ‘L. and A. Seràgnoli,’ S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ItalyCorrespondence[email protected]
 show all
Pages 247-253 | Received 03 Nov 2008, Accepted 11 Dec 2008, Published online: 01 Jul 2009

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Raoul Tibes & Ruben A. Mesa. (2011) Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. Leukemia & Lymphoma 52:7, pages 1178-1187.
Read now
Ayalew Tefferi. (2010) Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leukemia & Lymphoma 51:4, pages 576-582.
Read now
Ayalew Tefferi. (2009) JAK2V617F: more than a clonal marker?. Leukemia & Lymphoma 50:2, pages 154-155.
Read now

Articles from other publishers (22)

Tuba Ozkan Tekin, Denizhan Karis, Fatma Ates Alkan, Guven Cetin & Alev Meltem Ercan. (2022) Evaluation of trace elements in essential thrombocytosis and reactive thrombocytosis. Journal of Trace Elements in Medicine and Biology 73, pages 127034.
Crossref
Cigdem Yuce Kahraman, Gulden Sincan & Abdulgani Tatar. (2022) Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients. Medical Bulletin of Haseki 60:1, pages 26-32.
Crossref
Renato Sampaio Tavares, Alexandre Nonino, Katia Borgia Barbosa Pagnano, Ana Clara Kneese Virgilio do Nascimento, Monika Conchon, Laura Maria Fogliatto, Vaneuza Araújo Moreira Funke, Israel Bendit, Nelma Cristina Diogo Clementino, Maria de Lourdes Lopes Ferrari Chauffaille, Wanderley Marques Bernardo & Fabio Pires de Souza Santos. (2019) Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular. Hematology, Transfusion and Cell Therapy 41, pages 1-73.
Crossref
Barbara J. Bain, David M. Clark & Bridget S. Wilkins. 2019. Bone Marrow Pathology. Bone Marrow Pathology 267 345 .
Mehmet Erdem Alagüney, Funda Ceran, Mesude Falay, Simten Dağdaş & Gülsüm Özet. (2019) Esansiyel Trombositemi Hastalarında JAK2-V617F Mutasyonu ile Klinik Sonlanım Belirteçleri Arasındaki Ilişki. OSMANGAZİ JOURNAL OF MEDICINE 41:1, pages 81-86.
Crossref
Ercan ERSOY, Utku Erdem SOYALTIN, Ahmet PEKER, Ayfer ÇOLAK, Cengiz CEYLAN & Harun AKAR. (2018) Ischemia-Modified Albumin Levels in Patients With Essential ThrombocytosisEsansiyel Trombositozlu Hastalarda İskemi-Modifiye Albumin Düzeyleri. Konuralp Tıp Dergisi 10:3, pages 341-346.
Crossref
Roberto Latagliata, Nicola Polverelli, Alessia Tieghi, Giuseppe Alberto Palumbo, Massimo Breccia, Elena Sabattini, Loredana Villari, Mara Riminucci, Riccardo Valli, Lucia Catani, Giuliana Alimena, Emanuela Ottaviani, Angelo Fama, Giovanni Martinelli, Margherita Perricone, Marco Spinsanti, Michele Cavo, Nicola Vianelli & Francesca Palandri. (2018) Comparison of JAK2 V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology . Hematological Oncology 36:1, pages 269-275.
Crossref
Roberto Latagliata, Marco Montanaro, Michele Cedrone, Ambra Di Veroli, Francesca Spirito, Cristina Santoro, Sabrina Leonetti Crescenzi, Raffaele Porrini, Jonny Di Giandomenico, Nicoletta Villiv?Antonio Spadea, Angela Rago, Cinzia De Gregoris, Atelda Romano, Barbara Anaclerico, Marianna De Muro, Stefano Felici, Massimo Breccia, Enrico Montefusco, Antonino Bagnato, Giuseppe Cimino, Ignazio Majolino, Maria Gabriella Mazzucconi, Giuliana Alimena & Alessandro Andriani. (2017) High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research 156, pages 168-171.
Crossref
S Cerquozzi & A Tefferi. (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer Journal 5:11, pages e366-e366.
Crossref
Youwen Qin, Xiaorui Wang, Chuxian Zhao, Chun Wang & Yining Yang. (2015) The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. International Journal of Hematology 102:2, pages 170-180.
Crossref
M. Benguella-Benmansour, K. Boucherit, N. Benchikh, N. Mesli, N. Chabni, A. Messaoudi, A. Bekadja, Z. Boucherit & M. J. Mozziconacci. (2014) Prevalence of JAK2 V617F mutation in west algerian population with chronic myeloproliferative neoplasms: A multicenter studyPrévalence de la mutation JAK2V617F dans la population atteinte de néoplasmes myéloprolifératifs chroniques dans l’Ouest Algérien : une étude multicentrique. Journal Africain du Cancer / African Journal of Cancer 6:3, pages 138-144.
Crossref
Francesca PalandriNicola Polverelli, Lucia Catani, Michele Cavo & Nicola Vianelli. (2013) Update on the treatment of Ph-negative myeloproliferative neoplasms. International Journal of Hematologic Oncology 2:3, pages 251-262.
Crossref
Jacek Treliński, Krzysztof Chojnowski, Barbara Cebula-Obrzut & Piotr Smolewski. (2012) Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. Medical Oncology 29:4, pages 2388-2395.
Crossref
Sandra Malak, Myriam Labopin, Cecile Saint-Martin, Christine Bellanne-Chantelot & Albert Najman. (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells, Molecules, and Diseases 49:3-4, pages 170-176.
Crossref
Raoul Tibes, James M. Bogenberger, Kasey L. Benson & Ruben A. Mesa. (2012) Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. Molecular Diagnosis & Therapy 16:5, pages 269-283.
Crossref
Chad Cherington, James L. Slack, Jose Leis, Roberta H. Adams, Craig B. Reeder, Joseph R. Mikhael, John Camoriano, Pierre Noel, Veena Fauble, Jeffrey Betcher, Meagan S. Higgins, Ginger Gillette-Kent, Lisa D. Tremblay, Mary E. Peterson, Jane J. Olsen, Raoul Tibes & Ruben A. Mesa. (2012) Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leukemia Research 36:9, pages 1147-1151.
Crossref
Fiorina GionaLuciana Teofili, Maria Luisa MoletiMaurizio MartiniGiovanna PalumboAngela Amendola, Maria Gabriella MazzucconiAnna Maria TestiPatrizia PignoloniSonia Maria Orlando, Sara Capodimonti, Mauro NanniGiuseppe Leone, Luigi Maria LaroccaRobin Foà. (2012) Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 119:10, pages 2219-2227.
Crossref
Francesca Palandri, Nicola Polverelli, Lucia Catani, Emanuela Ottaviani, Michele Baccarani & Nicola Vianelli. (2011) Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. British Journal of Haematology 156:5, pages 676-679.
Crossref
Raoul Tibes & Ruben Mesa. (2011) JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. Clinical Investigation 1:12, pages 1681-1693.
Crossref
A Tefferi. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:6, pages 1128-1138.
Crossref
Jacek Treliński, Agnieszka Wierzbowska, Anna Krawczyńska, Agata Sakowicz, Tadeusz Pietrucha, Piotr Smolewski, Tadeusz Robak & Krzysztof Chojnowski. (2010) Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. International Journal of Hematology 91:5, pages 792-798.
Crossref
Sebastian Ochsenreither, Mark Reinwald, Eckhard Thiel & Thomas Burmeister. (2012) Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. Molecular Diagnosis & Therapy 14:3, pages 185-190.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.